{"nctId":"NCT05074888","briefTitle":"Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.","startDateStruct":{"date":"2021-10-15","type":"ACTUAL"},"conditions":["Post-acute COVID-19 Syndrome"],"count":676,"armGroups":[{"label":"Prospekta","type":"EXPERIMENTAL","interventionNames":["Drug: Prospekta"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Prospekta","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Adults of either gender aged 18 to 65 years inclusive.\n2. Patients within 4-12 weeks of the confirmed COVID-19 onset .\n3. Symptoms of asthenia that appeared during or after an acute new coronavirus infection (COVID-19), persisting from 4 to 12 weeks from the onset of coronavirus infection.\n4. Presence of asthenia (≥36 on the FSS scale).\n5. Patients who agreed to use a reliable method of contraception during the study (for men and women with reproductive potential).\n6. Presence of a signed information sheet and informed consent form for participation in a clinical trial.\n\nExclusion Criteria:\n\n1. History / suspicion of cancer of any localization (with the exception of benign neoplasms).\n2. More than 75% of lung tissue damage during the period of COVID-19 disease (CT 4).\n3. Cerebrovascular diseases with the development of moderate to severe cognitive impairments.\n4. Uncontrolled arterial hypertension characterized by the following blood tension values: systolic blood pressure \\> 180 mm Hg and/or diastolic blood pressure \\> 110 mm Hg.\n5. Myocardial infarction, stroke in the previous 6 months.\n6. Nervous system disorders with persistent neurological impairment.\n7. Autoimmune diseases.\n8. Decompensated diseases of the cardiovascular system, liver, kidney, gastrointestinal tract, and metabolic, respiratory, endocrine or hematological diseases, peripheral vascular disorders.\n9. Any severe comorbidity which, in the opinion of the investigator, may affect patient participation in the clinical trial.\n10. Hypersensitivity to any of the components of the study drug.\n11. Hereditary lactose intolerance, lactose malabsorption, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.\n12. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial (for men and women with reproductive potential).\n13. Patients, who, from the investigator's point of view, will not comply with study observation requirements or study drug administration procedures..\n14. Prior history of mental illness, alcoholism or drug abuse, that the investigator's opinion, will interfere with successful study procedures.\n15. Use of any medications listed in \"Prohibited concomitant treatment\" within 1 week before enrollment.\n16. Participation in other clinical studies within 3 months prior to enrollment in the study.\n17. Patients who are related to any of the on-site research personnel directly involved in the conduct of the trial or are an immediate relative of the study investigator. \"Immediate relative\" means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).\n18. Participants who work for OOO \"NPF \"MATERIA MEDICA HOLDING\" (i.e. the company's employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the Mean FSS Score.","description":"Fatigue Severity Scale (FSS). Change in the mean FSS score after 4 weeks of treatment. The total score of the scale, which consists of 9 questions, varies between 9-63. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period. A total of 36 points and above indicate fatigue. A higher score is indicated high level of fatigue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":"6.9"},{"groupId":"OG001","value":"45.9","spread":"6.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":"9.2"},{"groupId":"OG001","value":"31.9","spread":"9.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":"9.5"},{"groupId":"OG001","value":"14.0","spread":"9.4"}]}]}]},{"type":"SECONDARY","title":"Change in Distance of the 6-minute Walk Test.","description":"Change in distance when performing the 6-minute walk test after 4 weeks of treatment. The test is carried out with the aim of objectively assessing the patient's physical tolerance. The patient should walk the maximum possible distance for himself at his own pace on a flat surface in 6 minutes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"426.4","spread":"119.2"},{"groupId":"OG001","value":"416.9","spread":"112.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"457.8","spread":"118.2"},{"groupId":"OG001","value":"444.7","spread":"110.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":"44.5"},{"groupId":"OG001","value":"27.8","spread":"38.1"}]}]}]},{"type":"SECONDARY","title":"Change in the Severity of Anxiety on the HADS Subscale.","description":"Hospital Anxiety and Depression Scale (HADS). Change in the severity of anxiety and depression on the HADS subscales after 4 weeks of treatment. The scale is composed of 14 statements serving 2 subscales: \"anxiety\" (odd items - 1, 3, 5, 7, 9, 11, 13) and \"depression\" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values:\n\n0-7 - \"norm\" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - \"subclinical anxiety / depression\"; 11 and above - \"clinical anxiety / depression\". The anxiety subscale ranges from 0 to 21, with higher values reflecting a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"4.1"},{"groupId":"OG001","value":"8.8","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"3.2"},{"groupId":"OG001","value":"6.0","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"3.2"},{"groupId":"OG001","value":"2.8","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Change in the Severity of Depression on the HADS Subscale.","description":"Hospital Anxiety and Depression Scale (HADS). Change in the severity of depression on the HADS subscale after 4 weeks of treatment. The scale is composed of 14 statements serving 2 subscales: \"anxiety\" (odd items - 1, 3, 5, 7, 9, 11, 13) and \"depression\" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values:\n\n0-7 - \"norm\" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - \"subclinical anxiety / depression\"; 11 and above - \"clinical anxiety / depression\". The depression subscale ranges from 0 to 21, with higher values reflecting a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"3.7"},{"groupId":"OG001","value":"8.3","spread":"3.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"2.9"},{"groupId":"OG001","value":"5.2","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"3.0"},{"groupId":"OG001","value":"3.1","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Change in the Mean FSS Score Within Follow-up Period.","description":"Change in mean FSS score over 4 weeks of follow-up period at the end of treatment. The total score of the scale, which consists of 9 questions, varies between 9-63. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period. A total of 36 points and above indicate fatigue. A higher score is indicated high level of fatigue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":"9.2"},{"groupId":"OG001","value":"31.9","spread":"9.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":"9.0"},{"groupId":"OG001","value":"25.0","spread":"10.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"6.3"},{"groupId":"OG001","value":"7.0","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Change in Distance of the 6-minute Walk Test Within Follow-up Period.","description":"Change in distance when performing the 6-minute walk test over a 4-week follow-up period at the end of treatment. The test is carried out with the aim of objectively assessing the patient's physical tolerance. The patient should walk the maximum possible distance for himself at his own pace on a flat surface in 6 minutes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"457.8","spread":"118.2"},{"groupId":"OG001","value":"444.7","spread":"110.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"472.9","spread":"116.5"},{"groupId":"OG001","value":"462.7","spread":"110.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":"32.1"},{"groupId":"OG001","value":"18.8","spread":"32.0"}]}]}]},{"type":"SECONDARY","title":"Change in the Severity of Anxiety on the HADS Subscales Within Follow-up Period.","description":"Change in the severity of anxiety on the HADS subscales over a 4-week follow-up period at the end of treatment. The scale is composed of 14 statements serving 2 subscales: \"anxiety\" (odd items - 1, 3, 5, 7, 9, 11, 13) and \"depression\" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values:\n\n0-7 - \"norm\" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - \"subclinical anxiety / depression\"; 11 and above - \"clinical anxiety / depression\". The anxiety subscale ranges from 0 to 21, with higher values reflecting a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"3.2"},{"groupId":"OG001","value":"6.0","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"2.8"},{"groupId":"OG001","value":"4.4","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"2.3"},{"groupId":"OG001","value":"1.6","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Change in the Severity of Depression on the HADS Subscales Within Follow-up Period.","description":"Change in the severity of depression on the HADS subscales over a 4-week follow-up period at the end of treatment.\n\nThe scale is composed of 14 statements serving 2 subscales: \"anxiety\" (odd items - 1, 3, 5, 7, 9, 11, 13) and \"depression\" (even items - 2, 4, 6, 8, 10, 12 , 14). Each statement corresponds to 4 answer options, reflecting the gradation of the severity of the sign and coded according to the increase in the severity of the symptom from 0 (no) to 3 (maximum severity). When interpreting the results, the total indicator for each subscale is taken into account, while there are 3 areas of its values:\n\n0-7 - \"norm\" (absence of reliably expressed symptoms of anxiety and depression); 8-10 - \"subclinical anxiety / depression\"; 11 and above - \"clinical anxiety / depression\". The depression subscale ranges from 0 to 21, with higher values reflecting a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"2.9"},{"groupId":"OG001","value":"5.2","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"2.6"},{"groupId":"OG001","value":"3.7","spread":"2.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"2.1"},{"groupId":"OG001","value":"1.5","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs (Pulse Rate (Heart Rate)).","description":"Based on medical records. Vital signs will be measured in a medical setting.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":"6.9"},{"groupId":"OG001","value":"73.4","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":"5.8"},{"groupId":"OG001","value":"71.9","spread":"5.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":"5.3"},{"groupId":"OG001","value":"71.4","spread":"5.5"}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs (Respiration Rate (Breathing Rate)).","description":"Based on medical records. Vital signs will be measured in a medical setting.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":"1.3"},{"groupId":"OG001","value":"16.4","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":"1.2"},{"groupId":"OG001","value":"16.2","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":"1.2"},{"groupId":"OG001","value":"16.2","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs (Blood Pressure).","description":"Based on medical records. Vital signs will be measured in a medical setting.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121.3","spread":"8.6"},{"groupId":"OG001","value":"120.9","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.1","spread":"8.4"},{"groupId":"OG001","value":"120.6","spread":"8.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.1","spread":"8.2"},{"groupId":"OG001","value":"120.4","spread":"7.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":"6.5"},{"groupId":"OG001","value":"75.8","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":"6.3"},{"groupId":"OG001","value":"75.9","spread":"6.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":"6.1"},{"groupId":"OG001","value":"75.4","spread":"5.9"}]}]}]},{"type":"SECONDARY","title":"Presence of Adverse Events (AEs).","description":"The number of participants with adverse events (AEs). Based on medical records.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"The Severity of AEs.","description":"The intensity (severity) of adverse events. Based on medical records.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"The Outcome of AEs.","description":"The outcome of adverse events. Based on medical records.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"AEs Causal Relationship to the Study Drug.","description":"The adverse events causal relationship to the study drug. Based on medical records.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":330},"commonTop":["Headache","Dizziness","Viral infection of the respiratory tract","Laboratory confirmed coronavirus infection COVID-19","BP above normal"]}}}